Hepatocyte growth factor promotes lymphatic vessel formation and function
Identifieur interne : 000041 ( Pmc/Curation ); précédent : 000040; suivant : 000042Hepatocyte growth factor promotes lymphatic vessel formation and function
Auteurs : Kentaro Kajiya [Suisse, États-Unis] ; Satoshi Hirakawa [États-Unis] ; Beijia Ma [États-Unis] ; Ines Drinnenberg [Suisse] ; Michael Detmar [Suisse, États-Unis]Source :
- The EMBO Journal [ 0261-4189 ] ; 2005.
Abstract
The lymphatic vascular system plays a pivotal role in mediating tissue fluid homeostasis and cancer metastasis, but the molecular mechanisms that regulate its formation and function remain poorly characterized. A comparative analysis of the gene expression of purified lymphatic endothelial cells (LEC) versus blood vascular endothelial cells (BVEC) revealed that LEC express significantly higher levels of hepatocyte growth factor receptor (HGF-R). Whereas little or no HGF-R expression was detected by lymphatic vessels of normal tissues, HGF-R was strongly expressed by regenerating lymphatic endothelium during tissue repair and by activated lymphatic vessels in inflamed skin. Treatment of cultured LEC with HGF promoted LEC proliferation, migration and tube formation. HGF-induced proliferation of LEC did not require vascular endothelial growth factor receptor-3 activation, and HGF-induced cell migration was partially mediated via integrin alpha-9. Transgenic or subcutaneous delivery of HGF promoted lymphatic vessel formation in mice, whereas systemic blockade of HGF-R inhibited lymphatic function. These results identify HGF as a novel, potent lymphangiogenesis factor, and also indicate that HGF-R might serve as a new target for inhibiting pathological lymphangiogenesis.
Url:
DOI: 10.1038/sj.emboj.7600763
PubMed: 16052207
PubMed Central: 1187946
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000041
Links to Exploration step
PMC:1187946Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hepatocyte growth factor promotes lymphatic vessel formation and function</title><author><name sortKey="Kajiya, Kentaro" sort="Kajiya, Kentaro" uniqKey="Kajiya K" first="Kentaro" last="Kajiya">Kentaro Kajiya</name><affiliation wicri:level="1"><nlm:aff id="O1">Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Hirakawa, Satoshi" sort="Hirakawa, Satoshi" uniqKey="Hirakawa S" first="Satoshi" last="Hirakawa">Satoshi Hirakawa</name><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Ma, Beijia" sort="Ma, Beijia" uniqKey="Ma B" first="Beijia" last="Ma">Beijia Ma</name><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Drinnenberg, Ines" sort="Drinnenberg, Ines" uniqKey="Drinnenberg I" first="Ines" last="Drinnenberg">Ines Drinnenberg</name><affiliation wicri:level="1"><nlm:aff id="O1">Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Detmar, Michael" sort="Detmar, Michael" uniqKey="Detmar M" first="Michael" last="Detmar">Michael Detmar</name><affiliation wicri:level="1"><nlm:aff id="O1">Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16052207</idno><idno type="pmc">1187946</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1187946</idno><idno type="RBID">PMC:1187946</idno><idno type="doi">10.1038/sj.emboj.7600763</idno><date when="2005">2005</date><idno type="wicri:Area/Pmc/Corpus">000041</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000041</idno><idno type="wicri:Area/Pmc/Curation">000041</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000041</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Hepatocyte growth factor promotes lymphatic vessel formation and function</title><author><name sortKey="Kajiya, Kentaro" sort="Kajiya, Kentaro" uniqKey="Kajiya K" first="Kentaro" last="Kajiya">Kentaro Kajiya</name><affiliation wicri:level="1"><nlm:aff id="O1">Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Hirakawa, Satoshi" sort="Hirakawa, Satoshi" uniqKey="Hirakawa S" first="Satoshi" last="Hirakawa">Satoshi Hirakawa</name><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Ma, Beijia" sort="Ma, Beijia" uniqKey="Ma B" first="Beijia" last="Ma">Beijia Ma</name><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author><author><name sortKey="Drinnenberg, Ines" sort="Drinnenberg, Ines" uniqKey="Drinnenberg I" first="Ines" last="Drinnenberg">Ines Drinnenberg</name><affiliation wicri:level="1"><nlm:aff id="O1">Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich</wicri:regionArea></affiliation></author><author><name sortKey="Detmar, Michael" sort="Detmar, Michael" uniqKey="Detmar M" first="Michael" last="Detmar">Michael Detmar</name><affiliation wicri:level="1"><nlm:aff id="O1">Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland</nlm:aff><country xml:lang="fr">Suisse</country><wicri:regionArea>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="O2">Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA</wicri:regionArea></affiliation></author></analytic><series><title level="j">The EMBO Journal</title><idno type="ISSN">0261-4189</idno><idno type="eISSN">1460-2075</idno><imprint><date when="2005">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The lymphatic vascular system plays a pivotal role in mediating tissue fluid homeostasis and cancer metastasis, but the molecular mechanisms that regulate its formation and function remain poorly characterized. A comparative analysis of the gene expression of purified lymphatic endothelial cells (LEC) versus blood vascular endothelial cells (BVEC) revealed that LEC express significantly higher levels of hepatocyte growth factor receptor (HGF-R). Whereas little or no HGF-R expression was detected by lymphatic vessels of normal tissues, HGF-R was strongly expressed by regenerating lymphatic endothelium during tissue repair and by activated lymphatic vessels in inflamed skin. Treatment of cultured LEC with HGF promoted LEC proliferation, migration and tube formation. HGF-induced proliferation of LEC did not require vascular endothelial growth factor receptor-3 activation, and HGF-induced cell migration was partially mediated via integrin alpha-9. Transgenic or subcutaneous delivery of HGF promoted lymphatic vessel formation in mice, whereas systemic blockade of HGF-R inhibited lymphatic function. These results identify HGF as a novel, potent lymphangiogenesis factor, and also indicate that HGF-R might serve as a new target for inhibiting pathological lymphangiogenesis.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">EMBO J</journal-id><journal-title>The EMBO Journal</journal-title><issn pub-type="ppub">0261-4189</issn><issn pub-type="epub">1460-2075</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16052207</article-id><article-id pub-id-type="pmc">1187946</article-id><article-id pub-id-type="pii">7600763</article-id><article-id pub-id-type="doi">10.1038/sj.emboj.7600763</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hepatocyte growth factor promotes lymphatic vessel formation and function</article-title><alt-title alt-title-type="short">HGF promotes lymphangiogenesis</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kajiya</surname><given-names>Kentaro</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hirakawa</surname><given-names>Satoshi</given-names></name><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ma</surname><given-names>Beijia</given-names></name><xref ref-type="aff" rid="O2">2</xref></contrib><contrib contrib-type="author"><name><surname>Drinnenberg</surname><given-names>Ines</given-names></name><xref ref-type="aff" rid="O1">1</xref></contrib><contrib contrib-type="author"><name><surname>Detmar</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="O1">1</xref><xref ref-type="aff" rid="O2">2</xref><xref ref-type="corresp" rid="c1">a</xref></contrib><aff id="O1"><label>1</label>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland</aff><aff id="O2"><label>2</label>Department of Dermatology, Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA</aff></contrib-group><author-notes><corresp id="c1"><label>a</label>Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Wolfgang-Pauli-Str. 10, HCI H303, 8093 Zurich, Switzerland. Tel.: +41 44 633 7361; Fax: +41 44 633 1364; E-mail: <email>michael.detmar@pharma.ethz.ch</email></corresp></author-notes><pub-date pub-type="ppub"><day>17</day><month>08</month><year>2005</year></pub-date><pub-date pub-type="epub"><day>28</day><month>07</month><year>2005</year></pub-date><volume>24</volume><issue>16</issue><fpage>2885</fpage><lpage>2895</lpage><history><date date-type="received"><day>14</day><month>01</month><year>2005</year></date><date date-type="accepted"><day>11</day><month>07</month><year>2005</year></date></history><copyright-statement>Copyright © 2005, European Molecular Biology Organization</copyright-statement><copyright-year>2005</copyright-year><abstract><p>The lymphatic vascular system plays a pivotal role in mediating tissue fluid homeostasis and cancer metastasis, but the molecular mechanisms that regulate its formation and function remain poorly characterized. A comparative analysis of the gene expression of purified lymphatic endothelial cells (LEC) versus blood vascular endothelial cells (BVEC) revealed that LEC express significantly higher levels of hepatocyte growth factor receptor (HGF-R). Whereas little or no HGF-R expression was detected by lymphatic vessels of normal tissues, HGF-R was strongly expressed by regenerating lymphatic endothelium during tissue repair and by activated lymphatic vessels in inflamed skin. Treatment of cultured LEC with HGF promoted LEC proliferation, migration and tube formation. HGF-induced proliferation of LEC did not require vascular endothelial growth factor receptor-3 activation, and HGF-induced cell migration was partially mediated via integrin alpha-9. Transgenic or subcutaneous delivery of HGF promoted lymphatic vessel formation in mice, whereas systemic blockade of HGF-R inhibited lymphatic function. These results identify HGF as a novel, potent lymphangiogenesis factor, and also indicate that HGF-R might serve as a new target for inhibiting pathological lymphangiogenesis.</p></abstract><kwd-group><kwd>angiogenesis</kwd><kwd>HGF</kwd><kwd>integrins</kwd><kwd>lymphangiogenesis</kwd><kwd>tissue repair</kwd></kwd-group><counts><page-count count="11"></page-count></counts></article-meta></front><floats-wrap><fig id="f1"><label>Figure 1</label><caption><p>Increased expression of HGF-R by LEC. (<bold>A</bold>–<bold>C</bold>) Quantitative real-time RT–PCR confirmed that three independently established lines of primary LEC (black bars) expressed high levels of mRNA of the major lymphatic lineage markers Prox1 and LYVE-1, but expressed low levels of the blood vascular lineage marker Flt-1, as compared to BVEC (white bars). (<bold>D</bold>) LEC expressed over two-fold higher levels of HGF-R mRNA than BVEC, as determined by real-time RT–PCR. (<bold>E</bold>) Immunoprecipitation and Western blot analyses demonstrated that LEC (right lane) expressed much higher levels of HGF-R protein, compared with BVEC (left lane). (<bold>F</bold>) Treatment of LEC with 30 ng/ml HGF (right lane) resulted in increased phosphorylation of HGF-R, compared to untreated cells (left lane). IP: immunoprecipitate.</p></caption><graphic xlink:href="7600763f1"></graphic></fig><fig id="f2"><label>Figure 2</label><caption><p>HGF-R is expressed by lymphatic vessels during inflammation and tissue repair. Double immunofluorescence stains for the lymphatic marker LYVE-1 (green) and for HGF-R (red) revealed little or no HGF-R expression by lymphatic vessels in normal mouse skin (<bold>A</bold>–<bold>C</bold>), whereas, in the inflamed skin of VEGF-A transgenic mice, indicated by LYVE-1-positive regions, enlarged lymphatic vessels (asterisks) also expressed HGF-R (<bold>D</bold>–<bold>F</bold>). HGF-R was also expressed by epidermal keratinocytes. At 21 days after induction of full-thickness wounds in mouse skin, several LYVE-1-positive, regenerating lymphatic vessels at the wound edge expressed HGF-R (<bold>G</bold>–<bold>I</bold>, inset <bold>H</bold>–<bold>L</bold>). Arrows (G–I) indicate the left border of the original wound area. Arrowheads indicate HGF-R-expressing lymphatic vessels. Scale bars: 100 μm.</p></caption><graphic xlink:href="7600763f2"></graphic></fig><fig id="f3"><label>Figure 3</label><caption><p>HGF-R is expressed by endothelial cells of lymph sacs during mouse embryonic development. (<bold>A, B</bold>) By E11.5, LYVE-1-expressing endothelial cells (green) of the anterior CV expressed little or no HGF-R (red), whereas HGF-R expression was detected within the pharyngeal region of the foregut and in mesenchymal cells (asterisk). (<bold>C, D</bold>) At E12.5, weak HGF-R expression was detected in some LYVE-1-positive endothelial cells of the anterior CV (arrowheads), whereas only occasional HGF-R expression was observed near the endothelium lining the primitive lymph sacs (ls). (<bold>E, F</bold>) At E14.5, HGF-R was expressed by the vast majority of LYVE-1-positive LEC. At this stage, HGF-R was weakly expressed by endothelial cells of the jugular vein (jv) and the artery, which were LYVE-1-negative. Scale bars: 100 μm.</p></caption><graphic xlink:href="7600763f3"></graphic></fig><fig id="f4"><label>Figure 4</label><caption><p>HGF promotes LEC proliferation and migration. (<bold>A</bold>) HGF induced proliferation of LEC (♦) in a dose-dependent manner, compared to untreated control cells. Proliferation was induced at a minimum effective concentration of 1 ng/ml HGF (<italic>P</italic><0.01). HGF induced higher levels of proliferation in LEC than in BVEC (▪) at all concentrations. (<bold>B</bold>) An HGF-R-blocking antibody potently inhibited the HGF-induced stimulation of LEC proliferation (<sup>***</sup><italic>P</italic><0.001). Incubation with a VEGFR-3 blocking antibody or control IgG did not affect HGF-induced proliferation. (<bold>C</bold>) Treatment of LEC with VEGF-C (500 ng/ml) induced phosphorylation of VEGFR-3, which was inhibited by incubation with an anti-human VEGFR-3-neutralizing antibody. Lysates were immunoprecipitated with phosphotyrosine antibodies PY99 or 4G10 and immunoblotted with VEGFR-3. VEGFR-3 signals demonstrate the presence of equal amounts of protein. IP: Immunoprecipitate, WB: Western blot. (<bold>D</bold>) HGF induced migration of LEC and BVEC with a minimal effective concentration of 3 ng/ml. Data represent mean values ±s.e.m. of three independent experiments (<sup>*</sup><italic>P</italic><0.05).</p></caption><graphic xlink:href="7600763f4"></graphic></fig><fig id="f5"><label>Figure 5</label><caption><p>HGF promotes LEC tube formation <italic>in vitro</italic> and lymphatic vessel formation <italic>in vivo</italic>. (<bold>A, B</bold>) Treatment of LEC with 3 and 30 ng/ml HGF promoted cord formation in response to overlay with type I collagen, compared with untreated control cultures. Data are expressed as mean values ±s.d. (<sup>***</sup><italic>P</italic><0.001). Control Matrigels (<bold>C</bold>) and those that contain HGF (<bold>D</bold>) were subcutaneously implanted in FVB mice. Immunostaining for the lymphatic-specific glycoprotein podoplanin (red) revealed pronounced formation of new lymphatic vessels (D; arrowheads) within HGF-containing matrigels at day 7 after implantation, whereas no lymphatic vessel formation was observed within control matrigels. (<bold>E–G</bold>) Double immunofluorescence analyses of mouse ear sections for LYVE-1 (green) and CD31 (red) showed induction of LYVE-1-positive lymphatic vessel formation at 14 days after implantation of HGF-containing slow-release pellets (F and G; arrowheads), but not that of control pellets (E). Systemic treatment with a blocking anti-VEGFR-3 antibody (G) did not inhibit HGF-induced lymphatic vessel formation, as compared with control IgG treatment (F). Newly formed blood vessels were observed in all samples. P: Pellet. Scale bars: 100 μm (A, C–G).</p></caption><graphic xlink:href="7600763f5"></graphic></fig><fig id="f6"><label>Figure 6</label><caption><p>Enhanced formation of lymphatic vessels in HGF transgenic mice. Representative histologic images (H&E stain) of the ileum revealed vascular enlargement in HGF transgenic mice (<bold>B</bold>), as compared with wild-type mice (<bold>A</bold>). Immunofluorescence stains for the lymphatic vessel marker podoplanin (red) revealed enlarged central lacteals and enlarged submucosal lymphatic vessels in HGF transgenic mice (<bold>D</bold>), as compared with wild-type mice (<bold>C</bold>). Nuclei are labeled blue (Hoechst stain). (<bold>E–H</bold>) No major differences were observed in the histoarchitecture of the skin of HGF transgenic (F) and wild-type mice (E). However, podoplanin stains (red) revealed numerous enlarged lymphatic vessels in the skin of HGF transgenic mice (H) as compared with wild-type mice (G). Scale bars: 100 μm.</p></caption><graphic xlink:href="7600763f6"></graphic></fig><fig id="f7"><label>Figure 7</label><caption><p>HGF-R blockade inhibits lymphatic but not blood vessel enlargement in an experimental model of skin inflammation. (<bold>A, B</bold>) Double immunofluorescence analysis for LYVE-1 (green) and CD31 (red) revealed that the characteristic enlargement of lymphatic vessels at 24 h after induction of inflammation was inhibited in mice treated with a blocking anti-HGF-R antibody (B), as compared with the control IgG-treated group (A). Scale bars: 100 μm. (<bold>C–H</bold>) Computer-assisted morphometric analyses demonstrated that the relative tissue area occupied by lymphatic vessels (C) and the average size of lymphatic vessels (D) were significantly reduced after blockade of HGF-R (<sup>**</sup><italic>P</italic><0.01), compared to control IgG-treated mice (C, D). No significant differences of the density of lymphatic vessels were found between both groups (E), and there were no significant differences of the area occupied by blood vessels (F), the average blood vessel size (G) and the number of blood vessels (H).</p></caption><graphic xlink:href="7600763f7"></graphic></fig><fig id="f8"><label>Figure 8</label><caption><p>HGF promotes LEC migration via integrin alpha-9. (<bold>A</bold>) SYBR-Green-based quantitative real-time RT–PCR shows that the expression of stanniocalcin 1 and of integrin alpha-9 are significantly upregulated after treatment of LEC with HGF (H) as compared with control (C). The expression levels were normalized to those of β-actin. (<bold>B</bold>) Treatment of LEC with HGF induces cell migration, but coincubation of cells with an integrin alpha-9-specific blocking antibody prevents this migration (<sup>*</sup><italic>P</italic><0.05). Incubation with an HGF-R-blocking antibody also inhibited the induction of LEC migration by HGF (<sup>**</sup><italic>P</italic><0.01), whereas LEC migration in the absence of HGF was not affected by treatment with an integrin alpha-9-blocking antibody or an HGF-R-blocking antibody. Treatment with control IgG or combined treatment with blocking antibodies against the integrin alpha-1 and -2 had no effect on HGF-induced LEC migration. Data represent mean values ±s.e.m. (<italic>n</italic>=5 per group), and are representative of three independent experiments.</p></caption><graphic xlink:href="7600763f8"></graphic></fig></floats-wrap></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000041 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000041 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:1187946
|texte= Hepatocyte growth factor promotes lymphatic vessel formation and function
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:16052207" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |